SEC Filing Summary: Pieris Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on August 11, 2016, reporting events as of August 10, 2016. The filing serves to announce financial results for the second quarter ended June 30, 2016, via an attached press release (Exhibit 99.1). The registrant is incorporated in Nevada and headquartered in Boston, MA.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only indicates that such results are contained within the referenced press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer under Item 2.02 stating that the information, including the attached exhibit, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the quarter ended June 30, 2016, by reviewing the attached press release (Exhibit 99.1).
- Confirm the company's cash position and burn rate as of the quarter end.
- Review the press release for any updates on clinical trial progress or regulatory milestones.
- Note that the financial data in this 8-K is not incorporated by reference into other SEC filings.